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Background: To show effectiveness of low-dose splenic irradiation in symptomatic congestive splenomegaly.
Methods: Five patients were referred to our department for symptomatic congestive splenomegaly within three
years. Primary diseases were autoimmune hepatitis with liver cirrhosis (n = 2), cystic fibrosis (n = 1), granulomatous
liver disease (n = 1) and Werlhof disease with liver cirrhosis (n = 1). Mean age was 54 years (range: 36–67). Patients
received splenic irradiation with a total dose of 3 Gy (single dose: 0.5 Gy). One patient was re-irradiated after
long-term failure with the same treatment schedule.
Results: In four patients long term relief of splenic pain could be observed during the follow-up time of median 20
(range: 2–36) months. Four patients showed haematological response after irradiation with an increase of erythrocytes,
leucocytes and/or platelets. A slightly decrease in spleen size was found in two patients.
Conclusions: Low-dose splenic irradiation in symptomatic congestive splenomegaly is feasible and perhaps as effective
as in lympho-and myeloproliferative malignancies regarding pain relief and haematological response.
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Splenic irradiation has been widely used in palliative
treatment of symptomatic splenomegaly in patients with
lymphoid and myeloid malignancies as reported currently
by Kriz et al. in a large cohort of patients using different
fractionation regimens [1]. Apart from lymphoid and mye-
loid malignancies hypersplenism–characterized by painful
splenomegaly and cytopenia–can also occur as a secondary
phenomenon in a variety of benign disorders. Beside liver
transplantation as solely curative treatment of the primary
liver disease, splenectomy and minimal invasive proce-
dures such as splenic embolisation are well-tried treatment
options for patients with symptomatic congestive spleno-
megaly, e.g. secondary due to portal hypertension from
liver cirrhosis. However, these treatment options carry a
high risk of possible complications [2]. Splenic irradiation
constitutes an alternative non-invasive treatment option.* Correspondence: Bruns.Frank@mh-hannover.de
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unless otherwise stated.Recently, Weinmann et al. analyzed splenic irradiation in
autoimmune disorders like autoimmune thrombocyto-
penia or autoimmune hemolytic anemia with promising
results [3]. Splenic irradiation for symptomatic congestive
splenomegaly is unusually and there are only two reports
on this subject in the Anglophone literature. This report of
five patients aims to confirm the published data in particu-
lar regarding the potential of symptom control.Methods
In the recent four years, five patients (female: 2, male: 3)
with symptomatic congestive splenomegaly received splenic
irradiation as an individual treatment approach. Patients
had contraindications for alternative treatment options
or refused interventional approaches. Primary diseases
were autoimmune hepatitis with consecutive liver cir-
rhosis (n = 2), cystic fibrosis (n = 1), granulomatous liver
disease (n = 1) and M. Werlhof with liver cirrhosis (n = 1).
Mean age was 54 years (range: 36–67). All patients and
treatment parameters are summarized in Table 1.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients and treatment characteristics
Patient number 1 2 3/3a 4 5
Sex (male/female) m m f f m
Age (years) 56 36 49 61 67
Primary disease Autoimmune hepatitis Cystic fibrosis Autoimmune hepatitis Granulomatous liver disease M. Werlhof with
liver cirrhosis
Single/total dose 0.5/3.0 Gy 0.5/3.0 Gy 0.5/3.0 Gy Second course
(3a): 0.5/3.0 Gy
0.5/3.0 Gy 0.5/3.0 Gy
Follow-up (months) 21 35 24 (36) and (3a) 12 7 2
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Computertomography-based treatment planning using
6-or 10 MV linac photons. Total dose given was 3.0 Gy
with single fractions of 0.5 Gy two or three times a week.
Patient 3 had a second course of splenic irradiation after
long-term failure (progressive pain, 2 years after radio-
therapy) with the same treatment schedule.
Beside pain evaluation (four-point scale: no pain-mild
pain-moderate pain-severe pain) size measurement of the
spleen was performed by sonography. Blood counts were
monitored before each fraction and during follow-up visits.
Consent
Informed consent was obtained from the patient for the
publication of this report.
Results
Median follow-up was 20 months (range: 2–36). The re-
sults are summarized in Table 2. In all patients with prece-
dent splenic pain long term pain relief could be observed
(decrease from severe pain to no pain in patient 2; from
mild pain to no pain in patient 1 and 3 [second serie]; and
from moderate pain to mild pain in patient 5); in two pa-
tients with painless abdominal feeling of pressure no im-
provement arose. A slight decrease in splenic size of about
10% was seen in 2 patients (patient 1: length: 24 cm to
22 cm; patient 2: length: 21.6 cm to 20.0 cm); in two fur-
ther patients the splenic size was stable after a shortTable 2 Treatment results
Patient number 1 2
Relief of splenic pain + +
Haematological response + –
Decrease of spleen size + +
WBC before/after RT 1.9/2.1 5.0/3.9
Δ +11% Δ –22%
Hb before/after RT 11.7/14.1 12.0/12.7
Δ +21% Δ +6%
Plts before/after RT 36/44 24/13
Δ +23% Δ –45%
WBC: white blood cells (103/μl), Hb: hemoglobin (g/dl), Plts: platelets (103/μl), *painltemporary decrease. For two patients (including patient 3
after second irradiation) no follow-up sonography was
available to date. Hematological response after irradiation
with an increase of erythrocytes, leucocytes and/or plate-
lets could be observed in four patients (see Table 2). Pa-
tient 2 had a decrease of blood cells immediately after
irradiation but hematological parameters remained stable
during long term follow-up; no hematological effect was
observed in patient 3 after second irradiation. Neither
acute side effects of irradiation like nausea nor any late se-
quela has occurred so far.
Discussion
Splenomegaly is a frequent finding in patients with liver
disease due to venous congestion as a consequence of
portal hypertension; hypersplenism is characterized by
congestive splenomegaly and secondary a reduction of
erythrocytes, leucocytes and/or platelets due to splenic
pooling/sequestion [2]. In patients with poor liver func-
tion a splenectomy is often not possible. Alternatively,
mimimal invasive procedures such as partial splenic em-
bolisation and transjugular intrahepatic portosystemic
shunt (TIPS) implantation are used to reduce portal ven-
ous pressure [2,4,5]. Radiofrequency ablation (RFA) and
microwave (MW) ablation of splenic parenchyma – as less
radical techniques–are also applicable in symptomatic con-
gestive splenomegaly [6,7]. None of these procedures pro-
vide convincing results and are all associated with the3 3a 4 5
* + * +
+ – + +
– n.a. – n.a.
1.6/2.5 3.7/2.4 3.3/4.1 2.5/2.6
Δ +57% Δ –35% Δ +25% Δ +4%
9.1/12.1 12.7/11.2 12.5/13.6 11.4/11.2
Δ +33% Δ –11% Δ +9% Δ –1%
24/30 29/29 72/91 37/52
Δ +25% Δ ±0% Δ +27% Δ +38%
ess feeling of abdominal pressure, −: no effect, n.a.: not available.
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tion, abscess formation, pain, bleeding and sepsis.
Splenic irradiation is a well-established palliative treat-
ment option in patients with lympho-and myeloproliferative
malignancies presenting with symptomatic splenomegaly
[1,8]. In addition, radiotherapy is known to be effective in a
large variety of degenerative and hyperproliferative benign
conditions [9]. In terms of hypersplenism due to splenic
congestion the value of radiotherapy is limited to two case
series as illustrated below [10,11].
In all patients with precedent splenic pain treated with
radiotherapy we observed a long-term pain relief. In
addition we found an improvement of hematological pa-
rameters, particularly of platelets in four patients and a
slightly decrease of spleen size of about 10% in two
patients.
Until now, only two case series are reported in the
Anglophone literature, which analyse 5 and 8 patients
respectively treated with splenic irradiation for symp-
tomatic congestive splenomegaly [10,11]. Both achieved
outcomes similar to ours in terms of pain relief (Kenawi:
8 of 8 patients [100%]; Liu: 2 of 2 [100% of the patients
with precedent pain]; 3 patients had precedent painless
splenomegaly) and increase of platelets (Kenawi: 3 of 8
patients; Liu: 5 of 5 patients) after splenic irradiation.
The mean follow-up of 4 and 19 months respectively
was quite short compared to 20 months in our analysis.
The applied total dose was significantly higher with 12 Gy
in 8 fractions (single doses of 1.5 Gy, five times a week) in
the serie of Liu et al. [11], while Kenawi et al. [10] applied
different total doses from 3.0 to 23.0 Gy (mean total dose
approximately 12 Gy; single doses ranged from 0.5 to
1.5 Gy). Moreover, in all reported patients there was no
correlation between clinical response and change in spleen
size observed.
Osorio et al. [12] reported another case of painful
splenomegaly due to Eisenmenger’s syndrome. Their pa-
tient was treated with splenic irradiation with a very
high total dose of 40 Gy and daily single doses of 2.5 Gy.
The patient achieved good pain relief and marked reduc-
tion of spleen size but he died 4.5 months after radiother-
apy due to complications of acute cholecystitis. However,
very high-dose splenic irradiation as performed in this
case is debatable and seems inappropriate to achieve
symptom control in such a palliative setting.
For splenic irradiation in lympho-and myeloprolifera-
tive malignancies a large variation of different schedules
is used with single doses from 0.1 to 2 Gy and total doses
of 0.3–16 Gy and no consensus recommendations exist
concerning total dose and fractionation regimes until now
[1,13]. In our series we showed that a significant lower
dose of 3.0 Gy is sufficient to achieve suitable pain relief
and hematological response compared to higher doses
(12 Gy and more) reported by Kenawi and Liu et al. Inaddition, prescription of lower doses preserves the poten-
tial of re-irradiation in cases of treatment failure in this
palliative setting, as it was seen in patient 3.
The exact mechanism how splenic irradiation exerts its
effects in splenomegaly is poorly understood. While splenic
irradiation is usually considered as a local treatment only
with direct effects on the spleen, it also induces systemic
effects, which includes problematic symptoms and life-
threatening pancytopenia; mechanisms believed to contrib-
ute to these effects include direct radiation-induced cell
death, immune modulation via selective reduction in
lymphocyte subsets, and cytokine induction [13,14].
So far, in accordance with the literature data we ob-
served in our case series no clinically relevant early or late
toxicity. Particularly, no hematologic toxicities > CTC II°
occurred.
Conclusions
As shown for lympho-and myeloproliferative malignan-
cies before, low-dose splenic irradiation seems to be ef-
fective in treating symptomatic congestive splenomegaly
for patients with contraindications for splenectomy and
embolisation or refusal of interventional treatment. This
safe and well-tolerated treatment warrants further study.
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